{"id":"mk0826-duration-of-treatment-8-weeks","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3918117","moleculeType":"Small molecule","molecularWeight":"455.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly disclosed mechanism details for MK0826, the exact molecular target and pharmacological action cannot be reliably specified. The drug is in phase 3 development by Merck Sharp & Dohme LLC with an 8-week treatment duration in the trial design.","oneSentence":"MK0826 is a selective inhibitor of a specific molecular target being evaluated in phase 3 clinical trials.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:43.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00481702","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12","conditions":"Intra-abdominal Infection","enrollment":300},{"nctId":"NCT00389987","phase":"PHASE3","title":"Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09","conditions":"Complicated Intra-Abdominal Infections","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0826, /Duration of Treatment : 8 Weeks","genericName":"MK0826, /Duration of Treatment : 8 Weeks","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}